Benzodiazepine receptor Inhibitors
1 drugsAbout Benzodiazepine receptor
The Benzodiazepine receptor is a key component of the central nervous system (CNS). It modulates the effects of the neurotransmitter GABA, influencing sedative, anxiolytic, and muscle relaxant responses.
Currently, there is no genetic evidence available linking the Benzodiazepine receptor to specific diseases. However, its therapeutic importance is highlighted by existing drugs targeting it for CNS-related conditions.
The Benzodiazepine receptor is targeted by one FDA-approved drug, FELBAMATE, a small molecule. ANI PHARMS holds the approval for FELBAMATE, which has three indications.
Top Benzodiazepine receptor Drugs
ANI PHARMS is the sole company with an approved drug targeting the Benzodiazepine receptor.
Low competition suggests a potential market entry opportunity, but also indicates possible challenges in the target space.
Benzodiazepine receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Benzodiazepine receptor, using small molecule modality.
The exclusive use of small molecules indicates a whitespace opportunity for alternative modalities like antibodies or peptides.
Benzodiazepine receptor Drug Approval Timeline (2011 - 2011)
The first and most recent drug approval for this target was FELBAMATE in 2011.
A single approval over a decade ago suggests a saturated market or challenges in developing new therapies for this target.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Full summary • All drugs • Genetic evidence • Trials • Timeline